Cubist Pharmaceuticals (CBST), Durata Therapeutics, Inc. (DRTX) PT Raised at BofA/Merrill Lynch
Tweet Send to a Friend
BofA/Merrill Lynch analyst Steve Byrne raised his price target on Buy-rated Cubist Pharmaceuticals (NASDAQ: CBST) to $89.00 (from $84.00) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
